Roselaine Campos Targino

Papers

Total Citations

H-Index

About

Roselaine Campos Targino is a dedicated biotechnologist and pharmaceutical researcher whose work focuses on the development and characterization of biosimilar monoclonal antibodies, particularly for inflammatory diseases. Her most cited study, "A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential" (2018), has garnered 5 citations and represents a significant contribution to the field of biologics manufacturing. In this work, Targino and her team successfully engineered a Chinese hamster ovary (CHO) cell line capable of producing an anti-TNFα antibody with properties closely matching the reference product, addressing critical challenges in biosimilar development such as cell line stability, productivity, and product quality. This research has practical implications for reducing the cost of biologic therapies for conditions like rheumatoid arthritis and Crohn's disease, making treatment more accessible. Targino’s work exemplifies the intersection of cell engineering, protein expression, and therapeutic innovation, offering a scalable platform for biosimilar production. Her contributions are valuable for students and researchers interested in mammalian cell culture, recombinant protein expression, and the regulatory pathway for biosimilars, highlighting the meticulous science behind affordable biologic medicines.